NA
DTIL icon

NewEdge Advisors’s Precision BioSciences DTIL Stock Holding History

NewEdge Advisors’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-22
Closed -$90 – 4216
2025
Q4 		$90 Hold
22
– – ﹤0.01% 4158
2025
Q3 		$120 Hold
22
– – ﹤0.01% 4025
2025
Q2 		$91 Hold
22
– – ﹤0.01% 3913
2025
Q1 		$103 Hold
22
– – ﹤0.01% 3826
2024
Q4 		$83 Hold
22
– – ﹤0.01% 3791
2024
Q3 		$194 Hold
22
– – ﹤0.01% 3686
2024
Q2 		$211 Sell
22
-26
-54% -$306 ﹤0.01% 3642
2024
Q1 		$644 Sell
48
-41
-46% -$502 ﹤0.01% 3558
2023
Q4 		$971 Buy
89
+84
+1,680% +$906 ﹤0.01% 3472
2023
Q3 		$56 Hold
5
– – ﹤0.01% 3390
2023
Q2 		$86 Hold
5
– – ﹤0.01% 3427
2023
Q1 		$123 Sell
5
-107
-96% -$3.53K ﹤0.01% 3334
2022
Q4 		$3.82K Buy
+112
New +$4.43K ﹤0.01% 2674

Other funds holding DTIL

OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

NewEdge Advisors's DTIL Position: Q1 2026 in Review

NewEdge Advisors sold out of Precision BioSciences (DTIL) in Q1 2026, closing a stake of 22 shares — an estimated $90 sold.

NewEdge Advisors first reported a position in DTIL in Q4 2022 and held it in 13 quarters. The position peaked at $3.82K in Q4 2022. 78 funds tracked by Wall St. Rank hold DTIL as of Q1 2026.

  • NewEdge Advisors reported no remaining Precision BioSciences position as of Q1 2026 after selling out during the quarter.
  • NewEdge Advisors sold 22 Precision BioSciences shares in Q1 2026, an estimated $90.
  • NewEdge Advisors first reported a position in Precision BioSciences in Q4 2022 and held it in 13 quarters.
  • NewEdge Advisors's Precision BioSciences position peaked at $3.82K in Q4 2022.
  • 78 funds tracked by Wall St. Rank held Precision BioSciences as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.